{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:49:41Z","timestamp":1761176981109,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.tracli.2020.11.003","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T20:45:14Z","timestamp":1607114714000},"page":"89-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effective and safe off-label use of caplacizumab treatment in a middle-aged obese male"],"prefix":"10.1016","volume":"28","author":[{"given":"A.","family":"Ostuni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Tiscia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Battista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Favuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Montinaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Pronzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cappucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Fischetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gesualdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Grandone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2020.11.003_bib0060","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tracli.2020.11.003_bib0065","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2020.11.003_bib0070","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.tmrv.2019.06.005","article-title":"Taking empiricism out of immune thrombotic thrombocytopenic purpura: current and future treatment strategies","volume":"33","author":"Mazepa","year":"2019","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tracli.2020.11.003_bib0075","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/14712598.2019.1650908","article-title":"Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment","volume":"19","author":"le Besnerais","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.tracli.2020.11.003_bib0080","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720902904","article-title":"Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura","volume":"11","author":"Hanlon","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.tracli.2020.11.003_bib0085","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference centre experience","volume":"23","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.tracli.2020.11.003_bib0090","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.tracli.2020.11.003_bib0095","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11239-018-1674-6","article-title":"Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy","volume":"46","author":"Tiscia","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.tracli.2020.11.003_bib0100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2020.11.003_bib0105","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720902904","article-title":"Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura","author":"Hanlon","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.tracli.2020.11.003_bib0110","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","article-title":"ADAMTS13 and VWF activities guide individualised caplacizumab treatment in patients with aTTP","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782020301622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782020301622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:38:48Z","timestamp":1761129528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782020301622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1246782020301622"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2020.11.003","relation":{},"ISSN":["1246-7820"],"issn-type":[{"type":"print","value":"1246-7820"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effective and safe off-label use of caplacizumab treatment in a middle-aged obese male","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2020.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}